Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has entered into a strategic partnership with The Leukemia & Lymphoma Society® to advance the development of a novel BET inhibitor for the treatment of patients with hematologic malignancies.
More...
More...